Concordia’s Photodynamic Therapy Laser Receives Premarket Approval
OAKVILLE, Ontario, July 19, 2016 — Concordia International Corp. said that the U.S. Food and Drug Administration has approved the Company's premarket approval application for its Photofrin 630 PDT (photodynamic therapy) Laser.
PDT with Photofrin is a light-based cancer treatment that combines the photosensitizing drug Photofrin (porfimer sodium) with a specific wavelength of laser light to attack cancer cells.
Concordia said the newly approved laser — designed for use with Photofrin to treat esophageal cancer, Barrett's Esophagus and non-small cell lung cancer — has been reengineered with new controls and peripheral systems, while maintaining the same specifications with minimal changes to the treatment procedures.
The company is also evaluating Photofrin as a potential treatment for cholangiocarcinoma, or bile duct cancer, which is a rare disease affecting approximately 2,000 to 3,000 patients annually in the U.S.
MORE FROM PHOTONICS MEDIA